Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Bluejay Diagnostics, Inc. (BJDX) had Consolidated Net Income/Loss of $-9.95M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-9.95M |
|
-- |
|
-- |
|
$10.31M |
|
$-10.31M |
|
$0.36M |
|
$-9.95M |
|
$-9.95M |
|
$-9.95M |
|
$-9.95M |
|
|
Consolidated Net Income/Loss |
$-9.95M |
$-9.95M |
|
$-10.31M |
|
$-9.53M |
|
0.14M |
|
0.14M |
|
$-72.64 |
|
$-72.64 |
|
| Balance Sheet Financials | |
$3.22M |
|
$1.29M |
|
$1.65M |
|
$4.87M |
|
$1.77M |
|
-- |
|
$0.20M |
|
$1.97M |
|
$2.89M |
|
$2.89M |
|
$2.89M |
|
0.15M |
|
| Cash Flow Statement Financials | |
$-8.31M |
|
$-0.70M |
|
$1.11M |
|
$10.12M |
|
$2.21M |
|
$-7.91M |
|
$0.19M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.82 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.02M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-343.85% |
|
-343.85% |
|
-204.45% |
|
-343.85% |
|
$18.69 |
|
$-65.80 |
|
$-60.66 |
|